Objective:To investigate the clinical efficacy of colon cancer patients with liver and lung metastases by body gamma knife. Methods: During January 2009 to January 2011, 58 cases of colon cancer patients with liver and lung metastases in our hospital were randomly divided into the control group and the observation group. A total of 28 patients with 113 metastases in the control group were treated with systemic chemotherapy alone, and 30 patients with 116 metastases in the observation group were treated with body gamma knife treatment. After treatment, recent therapeutical effect, one year, two year and three-year local control rates and survival rates, serum carcino-embryonic antigen (CEA) and adverse changes of the two groups were compared. Results: The overall response rate (84.5%) of the observation group was significantly higher than that of the control group (49.6%) (P < 0.05). The serum CEA concentrations (3.8 ± 1.3 ng/ml) after treatment of the observation group was significantly lower than that of the control group (7.3 ± 3.2 ng/ml)(P < 0.05). The local control rates of one year (96.7%), two years (90.0%), three years (86.7%) of the observation group were significantly higher than those of the control group (85.7%, 64.3% and 35.7%) (all P < 0.05). The survival rates of one year (73.3%), two years (36.7%), three years (20.0%) of the observation group were significantly higher than those in the control group (64.3% , 28.6% and 7.1%) (all P < 0.05). The gastrointestinal reactions, hematologic toxicity, and liver and kidney toxicity incidence (20.0%, 13.3% and 6.7%) of the observation group were significantly lower than those of the control group (64.3%, 50.0 % and 35.7%) (all P < 0.05). Conclusion: The clinical efficacy of colon cancer patients with liver and lung metastases by body gamma knife was significantly effective, safe, and worthy of clinical application.